Market cap
$70 Mln
Recently Viewed
Clear AllMarket cap
$70 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-19 Mln
ROE
-0.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.8
Debt to Equity
0
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
53,939,400
CFO
$-224.74 Mln
EBITDA
$-272.24 Mln
Net Profit
$-268.43 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
| 145.3 | -1.5 | 286.8 | 90.9 | -28.9 | -29.1 | -- |
|
BSE Sensex*
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
| -81.6 | -12.7 | -45.4 | 103.4 | -76.1 | -19.7 | 54.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
|
1.3 | 70.1 | 0.0 | -37.0 | -- | -98.4 | -- | 0.5 |
| 0.7 | 5.0 | 2.0 | 17.2 | -618.4 | -- | -- | 7.5 |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is... developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc. Read more
Chairman & CEO
Mr. Armando Anido MBA
Chairman & CEO
Mr. Armando Anido MBA
Headquarters
Devon, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Zynerba Pharmaceuticals Inc (ZYNE) is $1.30 (NASDAQ) as of 13-Oct-2023 09:30 EDT. Zynerba Pharmaceuticals Inc (ZYNE) has given a return of -28.85% in the last 3 years.
Since, TTM earnings of Zynerba Pharmaceuticals Inc (ZYNE) is negative, P/E ratio is not available.
The P/B ratio of Zynerba Pharmaceuticals Inc (ZYNE) is 0.54 times as on 08-Nov-2023, a 88 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.69
|
0.52
|
|
2021
|
-3.08
|
1.63
|
|
2020
|
-1.92
|
1.61
|
|
2019
|
-4.46
|
1.85
|
|
2018
|
-1.31
|
0.91
|
The 52-week high and low of Zynerba Pharmaceuticals Inc (ZYNE) are Rs -- and Rs -- as of 22-Apr-2026.
Zynerba Pharmaceuticals Inc (ZYNE) has a market capitalisation of $ 70 Mln as on 08-Nov-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Zynerba Pharmaceuticals Inc (ZYNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.